Search

Author/Creator Kurman, Michael

1. 797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel). (10th December 2020)

Authors:
Khushalani, Nikhil; Brohl, Andrew; Markowitz, Joseph; Bazhenova, Lyudmila; Daniels, Gregory; Yeckes-Rodin, Heather; Fu, Siqing; McCormick, Lori; Kurman, Michael; Gillings, Mireille; Lee, Gloria; Eroglu, Zeynep
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A476
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Issue 8 (2nd July 2020)

Authors:
Garcia-Manero, Guillermo; Pemmaraju, Naveen; Alvarado, Yesid; Naqvi, Kiran; Ravandi, Farhad; Jabbour, Elias; De Lumpa, Ricardo; Kantarjian, Hagop; Advani, Anjali; Mukherjee, Sudipto; Gerds, Aaron; Carraway, Hetty E.; Nazha, Aziz; Iwamura, Hiroyuki; Murase, Motohiko; Bavisotto, Linda; Kurman, Mich...
Journal:
Leukemia & lymphoma
Issue:
Volume 61:Issue 8(2020)
Page Start:
1943
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search